Leman Cardiovascular announces the start of clinical trials

Leman Cardiovascular is an international biomedical device company, founded in late 2004, present in Europe and in the United States. The company was set up to create the third generation biological heart valve and thereby respond to an unmet surgical need. An estimated 17 million people die of cardiovascular heart diseases every year. Heart valve disease affects some half a million people worldwide.
 
Leman Cardiovascular has developed the Kalangos heart valve. Clinical trials in humans will start in Europe in the third quarter of 2012. Pre-clinical study results have shown superior performance characteristics such as:
1. Ease of implantation: Because of the innovative design, based on an internal titanium core, surgeons can easily handle and position the valve, reducing the duration of both the surgical procedure and recovery time. Hospital costs should be reduced.
 
2. High performance: Because of the No-Stress fixation Technology (NST) and its unique Double Triangle Geometry (DTG), the Kalangos valve showed enhanced in vitro hemodynamic performance (plus 20 to 25%) when compared to existing best in class valves in bench tests. This high hemodynamic performance should result in faster recovery of normal heart function.
 
3. Durability: Kalangos valves are processed by a No-Stress Tissue (NST) treatment technology that has historically demonstrated the longest durability for heart valves.